【Abstract】Objective To investigate the efficacy of indapamide combined with irbesartan on patients with hypertension complicated with congestive heart failure (CHF) and its effects on coagulation fibrinolysis system.Methods 86 patients with hypertension and CHF were selected and randomly grouped, including 43 cases in control group and 43 cases in observation group. Control group was treated with irbesartan, and observation group was treated with indapamide tablets on this basis. The blood pressure level and cardiac function were compared between the two groups before treatment and after 3 months of treatment, and the clinical efficacy of the two groups was evaluated, and the levels of platelet markers and plasma coagulationfibrinolysis system indexes were compared before treatment and after 3 months of treatment.Results After 3 months of treatment, the systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular enddiastolic diameter (LVEDD) and left ventricular endsystolic diameter (LVESD) in the two groups were significantly decreased compared with those before treatment (P＜005), while the left ventricular ejection fraction (LVEF) was significantly increased compared with that before treatment (P＜005. The indexes in observation group were significantly higher than those in control group (P＜005). The total clinical effective rate in observation group was significantly higher than that in control group (9535% vs 7907%, P＜005). After 3 months of treatment, the levels of platelet glycoprotein Ⅱb/Ⅲa receptor (PAC1) and Pselectin (CD62P) in the two groups were significantly decreased compared with those before treatment (P＜005). The levels of plasma DD, fibrinogen (FIB) and plasminogen activation inhibitor1 (PAI1) in the two groups were significantly decreased compared with those before treatment while the plasma tissuetype plasminogen activator (tPA) was significantly increased compared with that before treatment (P＜005). The changes of the above indexes in observation group were significantly greater than those in control group (P＜005). Conclusion Indapamide tablets combined with irbesartan can improve the clinical efficacy of hypertension with CHF, the blood pressure level and cardiac function of patients, and can significantly inhibit the levels of platelet PAC1 and CD62P, and improve the coagulationfibrinolysis system indexes.